Bioengineered chewing gum lowers cancer-linked microbes in oral cancer patients
Updated
Updated · SciTechDaily · May 2
Bioengineered chewing gum lowers cancer-linked microbes in oral cancer patients
6 articles · Updated · SciTechDaily · May 2
University of Pennsylvania-led researchers reported HPV fell 93% in saliva and 80% in oral rinse samples from head and neck squamous cell cancer patients.
Published in Scientific Reports, the findings suggest a low-cost adjuvant or preventive approach against infections tied to aggressive mouth and throat cancers, though clinical trials are still needed.
Might targeting oral microbes with plant-based drugs unlock new ways to fight other cancers or chronic diseases?
How soon could this gum reach patients, and what barriers remain before it becomes a mainstream cancer prevention tool?
Bioengineered Chewing Gum Achieves 93% Reduction in Oral HPV and Near-Complete Elimination of Cancer-Linked Bacteria in HNSCC Patients
Overview
In late 2025, Dr. Daniell's team revealed a bioengineered chewing gum that dramatically reduces key pathogens linked to head and neck cancer. The gum uses a lectin protein to aggregate and neutralize HPV, cutting its levels by over 90%, while an antimicrobial peptide kills harmful bacteria Porphyromonas gingivalis and Fusobacterium nucleatum to near zero. This targeted action preserves beneficial oral microbes, unlike radiation therapy which disrupts the oral microbiome. With its safe, affordable design, the gum shows promise as both an adjunct therapy and preventive measure for high-risk individuals. Ongoing clinical trials will confirm its effectiveness and safety, potentially transforming cancer care and prevention.